Trial Profile
An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin Dose With Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity During Treatment of Osteosarcoma Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Folitixorin (Primary) ; Folinic acid; Methotrexate
- Indications Osteosarcoma
- Focus Adverse reactions
- Sponsors Isofol Medical
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
- 11 Sep 2017 Results published in the Isofol Medical Media Release
- 11 Sep 2017 Results published in the Media Release